Chemotherapy and diagnosis of tuberculosis

Respiratory Medicine

Volumn 100, Issue 12, 2006, Pages 2085-2097

  Saltini, Cesare ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Clinical trials; MDR TB; TB chemotherapy; TB in vitro T cell assays; TB molecular diagnosis

Indexed keywords

AMINOGLYCOSIDE; AMINOSALICYLIC ACID; BACTERIAL DNA; BACTERIAL PROTEIN; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; ASIA; BACTERIAL TRANSMISSION; BACTERIUM IDENTIFICATION; BIOTECHNOLOGY; CLINICAL TRIAL; DIRECTLY OBSERVED THERAPY; DRUG COST; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; DRUG RESEARCH; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HOME CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; LUNG TUBERCULOSIS; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; OUTPATIENT CARE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SHORT COURSE THERAPY; SKIN TOXICITY; TUBERCULIN TEST; VESTIBULAR DISORDER;

AMBULATORY CARE; ANTIBIOTICS, ANTITUBERCULAR; ANTIBODIES, BACTERIAL; ANTITUBERCULAR AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HISTORY, 20TH CENTURY; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; MYCOBACTERIUM TUBERCULOSIS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; RIFAMPIN; TUBERCULOSIS;

EID: 33750859406     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2006.09.015     Document Type: Article

References (135)

1. Pfuetze K.H., Pyle M.M., Hinshaw H.C., and Feldman W.H. The first clinical trial of streptomycin in human tuberculosis. Am Rev Tuber 71 5 (1955) 752-754
2. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 2 (1948) 769-782
3. Medical Research Council. The prevention of streptomycin resistance by combined chemotherapy. BMJ (1952) 1157-1162
4. Isoniazid in pulmonary tuberculosis. Lancet 2 1 (1952) 19-21
5. Second report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Isoniazid in the treatment of pulmonary tuberculosis. BMJ 71 4809 (1953) 521-536
6. Seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee. Various combinations of isoniazid with streptomycin or with PAS in the treatment of pulmonary tuberculosis. BMJ 4911 (1955) 435-445
7. Tuberculosis Chemotherapy Centre Madras: Concurrent Comparison of Home and Sanatorium Treatment of Pulmonary Tuberculosis in South India. Bull World Health Organ 21 (1959) 51-144
8. Mount F.W., and Ferebee S.H. United States Public Health service cooperative investigation of antimicrobial therapy of tuberculosis, V. Report on thirty-two-week observations on combinations of isoniazid, streptomycin, and para-aminosalicylic acid. Am Rev Tuber 70 3 (1954) 521-526
9. A report from the British Medical Research Council. Co-operative controlled trial of a standard regimen of streptomycin. PAS and isoniazid and three alternative regimens of chemotherapy in Britain. Tubercle 54 (1973) 99-129
10. Isoniazid plus thioacetazone compared with two regimens of isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis in South Indian patients. Bull World Health Organ 34 4 (1966) 483-515
11. Kent P.W., Fox W., Miller A.B., Nunn A.J., Tall R., and Mitchison D.A. The therapy of pulmonary tuberculosis in Kenya: a comparison of the results achieved in controlled clinical trials with those achieved by the routine treatment services. Tubercle 51 1 (1970) 24-38
12. Maggi N., Pasqualucci C.R., Ballotta R., and Sensi P. Rifampicin: a new orally active rifamycin. Chemotherapy 11 5 (1966) 285-292
13. Covacev L., and Monzali G. Rifamycin SV in the therapy of tuberculosis. Clin Ter 39 6 (1966) 547-566
14. Lucchesi M., Pallotta G., Rossi P., and Sbampato M. The therapeutic action of rifampicin, a derivative of 3-(4-methyl-1-piperazinyl-iminomethyl)-rifamycin SV, in pulmonary tuberculosis. Ann Ist Carlo Forlanini 27 3 (1967) 199-227
15. Nitti V., Catena E., Bariffi F., and Delli Veneri F. Therapeutic activity of the Rifampicin in pulmonary tuberculosis. Arch Tisiol Mal Appar Respir 22 5 (1967) 417-462
16. East African/British Medical Research Council. Controlled clinical trial of four short course (6-months) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. Lancet 1974;2:237.
17. Fox W., and Mitchison D.A. Short course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 111 (1975) 325-353
18. East African/British Medical Research Council Investigation. A comparison of four short course (6-month) regimens of chemotherapy. Lancet 11 (1974) 1100
19. East African/British Medical Research Councils Study. Controlled clinical trial of five short-course (4-month) chemotherapy regiments in pulmonary turberculosis. Second report of the fourth study. Am Rev Respir Dis 123 2 (1981) 165-170
20. East and Central African/British Medical Research Council Fifth Collaborative Study. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: final report. Tubercle 67 1 (1986) 5-15
21. British Thoracic Association. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 126 3 (1982) 460-462
22. Algerian working group/British Medical Research Council cooperative study. Controlled clinical trial comparing a 6-month and a 12-month regimen in the treatment of pulmonary tuberculosis in the Algerian Sahara. Am Rev Respir Dis 129 6 (1984) 921-928
23. Clinical trial of 6-month and 4-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 62 2 (1981) 95-102
24. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months. Tubercle 60 4 (1979) 201-210
25. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Tubercle 63 2 (1982) 89-98
26. Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 136 6 (1987) 1339-1342
27. Singapore Tuberculosis Service/British Medical Research Council. Clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 132 2 (1985) 374-378
28. Santha T., Nazareth O., Krishnamurthy M.S., Balasubramanian R., Vijayan V.K., Janardhanam B., et al. Treatment of pulmonary tuberculosis with short course chemotherapy in South India-5-year follow up. Tubercle 70 4 (1989) 229-234
29. International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis regimens of chemotherapy: recommendations from the committee on treatment. Bull IUATLD 63 2 (1988) 60-64
30. WHO. Treatment of tuberculosis: guidelines for national programmes. Geneva: WHO, 2003:WHO/CDS/TB/2003.313.
31. WHO-TB PDF. WHO forty-fourth world health assembly, resolutions and decisions. Geneva, WHA44/1991/REC/1.
32. Benator D., Bhattacharya M., Bozeman L., Burman W., Cantazaro A., Chaisson R., et al. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 360 (2002) 528-534
33. Tam C.M., Chan S.L., Kam K.M., Goodall R.L., and Mitchison D.A. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis 6 1 (2002) 3-10
34. Burman W., Benator D., Vernon A., Khan A., Jones B., Silva C., et al. Tuberculosis Trials Consortium. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis. Am J Respir Crit Care Med 173 (2006) 350-356
35. Mwandumba H.C., and Squire S.B. Fully intermittent dosing with drugs for treating tuberculosis in adults. Cochrane Database Syst Rev 4 (2001)
36. Chang K.C., Leung C.C., Yew W.W., Chan S.L., and Tam C.M. Dosing schedules of six month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 174 (2006) 1153-1158
37. Weiner M., Benator D., Burman W., Peloquin C.A., Khan A., Vernon A., et al. Tuberculosis Trials Consortium Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 40 (2005) 1481-1491
38. Tappero J.W., Bradford W.Z., Agerton T.B., Hopewell P., Reingold A.L., Lockman S., et al. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 41 (2005) 461-469
39. Saltini C. Schedule or dosage? The need to perfect intermittent regimens for tuberculosis. Am J Respir Crit Care Med 174 (2006) 1067-1068
40. Centres for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Recomm Rep 47 (1998) 1-58
41. Geneva World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. HTM/TB 361 (2006)
42. Wilson T.M., de Lisle G.W., and Collins D.M. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol Microbiol 15 (1995) 1009-1015
43. Ramaswamy S., and Musser J.M. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 79 (1998) 3-29
44. Sander P., De Rossi E., Boddinghaus B., Cantoni R., Branzoni M., Bottger E.C., et al. Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance. FEMS Microbiol Lett 193 (2000) 19-23
45. De Rossi E., Branzoni M., Cantoni R., Milano A., Riccardi G., and Ciferri O. mmr, a Mycobacterium tuberculosis gene conferring resistance to small cationic dyes and inhibitors. J Bacteriol 180 (1998) 6068-6071
46. Ainsa J.A., Blokpoel M.C.J., Otal I., Young D.B., De Smet K.A.L., and Martin C. Molecular cloning and characterization of Tap, a putative multidrug efflux pump present in Mycobacterium fortuitum and Mycobacterium tuberculosis. J Bacteriol 180 (1998) 5836-5843
47. Heym B., Honore N., Truffot-Pernot C., Banerjee A., Schurra C., Jacobs Jr. W.R., et al. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344 (1994) 293-298
48. Mitchison D.A., and Nunn A.J. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133 (1986) 423-430
49. Tuberculosis Research Center, Madras and the National Tuberculosis Institute Bangalore. A controlled clinical trial of 3-and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Am Rev Respir Dis 134 (1986) 27-33
50. Goble M., Iseman M.D., Madsen L.A., Waite D., Ackerson L., and Horsburgh C.R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328 (1993) 527-532
51. Yew W.W., Chan C.K., Chau C.H., Tam C.M., Leung C.C., Wong P.C., et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 117 (2000) 744-751
52. Narita M., Alonso P., Lauzardo M., Hollender E.S., Pitchenik A.E., and Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 120 (2001) 343-348
53. Mitnick C., Bayona J., Palacios E., Shin S., Furin J., Alcantara F., et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348 (2003) 119-128
54. Leimane V., Riekstina V., Holtz T.H., Zarovska E., Skripconoka V., Thorpe L.E., et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet 365 (2005) 318-326
55. Tahaoglu K., Torun T., Sevim T., Atac G., Kir A., Karasulu L., et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 345 (2001) 170-174
56. Flament-Saillour M., Robert J., Jarlier V., and Grosset J. Outcome of multi-drug-resistant tuberculosis in France: a nationwide case-control study. Am J Respir Crit Care Med 160 2 (1999) 587-593
57. Subhash H.S., Ashwin I., Jesudason M.V., Abharam O.C., John G., Cherian A.M., et al. Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study. Indian J Chest Dis Allied Sci 45 (2003) 97-103
58. Park S.K., Lee W.C., Lee D.H., Mitnick C.D., Han L., and Seung K.J. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis 8 (2004) 361-368
59. WHO report. Global tuberculosis control: surveillance, planning, financing. Geneva: World Health Organization; 2004. HTM/TB/2004.331.
60. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance, 1999-2002. Anti-tuberculosis drug resistance in the world. Third global report. Geneva, World Health Organization, HTM/TB/2004.343.
61. Dye C., Espinal M.A., Watt C.J., Mbiaga C., and Williams B.G. Worldwide incidence of multidrug-resistant tuberculosis. J Infect Dis 185 (2002) 1197-1202
62. Bocchino M., Greco S., Rosati Y., Mattioli G., Marruchella A., De Mori P., et al. Cost determinants of tuberculosis management in a low-prevalence country. Int J Tuberc Lung Dis 10 2 (2006) 146-152
63. UNAIDS. 2006 Report on the global AIDS epidemic: executive summary World Health Organization, December 2005.
64. WHO report. Global tuberculosis control-surveillance, planning, financing, 2006. WHO/HTM/TB/2006.362.
65. Lane H.C., Depper J.M., Greene W.C., Whalen G., Waldmann T.A., and Fauci A.S. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med 313 (1985) 79-84
66. Mancino G., Placido R., Bach S., Mariani F., Montesano C., Ercoli L., et al. Infection of human monocytes with Mycobacterium tuberculosis enhances human immunodeficiency virus type 1 replication and transmission to T cells. J Infect Dis 175 6 (1997) 1531-1535
67. Pitchenik A.E., Cole C., Russell B.W., Fischl M.A., Spira T.J., and Snider Jr. D.E. Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med 101 (1984) 641-645
68. Selwyn P.A., Hartel D., Lewis V.A., Schoenbaum E.E., Vermund S.H., Klein R.S., et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 320 (1989) 545-550
69. Antonucci G., Girardi E., Raviglione M.C., and Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 274 2 (1995) 143-148
70. Frieden T.R., Sterling T., Pablos-Mendez A., Kilburn J.O., Cauthen G.M., and Dooley S.W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328 8 (1993) 521-526
71. Hawken M., Nunn P., Gathua S., Brindle R., Godfrey-Faussett P., Githui W., et al. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya. Lancet 342 (1993) 332-337
72. Sterling T.R., Alwood K., Gachuhi R., Coggin W., Blazes D., Bishai W.R., et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 13 (1999) 1899-1904
73. Vernon A., Burman W., Benator D., Khan A., and Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 353 9167 (1999) 1843-1847
74. Moro M.L., Gori A., Errante I., Infuso A., Franzetti F., Sodano L., et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. AIDS 12 9 (1998) 1095-1102
75. McElroy P.D., Southwick K.L., Fortenberry E.R., Levine E.C., Diem L.A., Woodley C.L., et al. Outbreak of tuberculosis among homeless persons coinfected with human immunodeficiency virus. Clin Infect Dis 36 10 (2003) 1305-1312
76. Maguire H., Ruddy M., Bothamley G., Patel B., Lipman M., Drobniewski F., et al. Multidrug resistance emerging in North London outbreak. Thorax 61 6 (2006) 547-548
77. Koch R. Die aetiologie der tuberculose. Berl Klin Wochenschr 15 (1882) 221-230
78. Koch M.L., and Cote R.A. Comparison of fluorescence microscopy with ziehl-neelsen stain stain for demonstration of acid-fast bacilli in smear preparations and tissue sections. Am Rev Respir Dis 91 (1965) 283-284
79. Rickman T.W., and Moyer N.P. Increased sensitivity of acid-fast smears. J Clin Microbiol 11 (1980) 618-620
80. Kox L.F.F., Rhienthong D., Miranda A.M., Udomsantisuk N., Ellis K., van Leeuwen J., et al. A more reliable PCR for detection of Mycobacterium tuberculosis in clinical samples. J Clin Microbiol 32 (1994) 672-678
81. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centres for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95.
82. Park C.H., Hixon D.L., Ferguson C.B., Hall S.L., Risheim C.C., and Cook C.B. Rapid recovery of mycobacteria from clinical specimens using automated radiometric technic. Am J Clin Pathol 81 (1984) 341-345
83. Abe C., Hosojima S., Fukasawa Y., Kazumi Y., Takahashi M., Hirano K., et al. Comparison of MB-Check, BACTEC, and egg-based media for recovery of mycobacteria. J Clin Microbiol 30 (1992) 878-881
84. Saiki R.K., Scharf S., Faloona F., Mullis K.B., Horn G.T., Erlich H.A., et al. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230 (1985) 1350-1354
85. Brisson-Noël A., Gicquel B., Lecossier D., Lévy-Frèbault V., Nassif X., and Hance A.J. Rapid diagnosis of tuberculosis by amplification of mycobacterial DNA in clinical samples. Lancet 2 (1989) 1069-1071
86. Eisenach K.D., Cave D.M., Bates J.H., and Crawford J.T. Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis. J Infect Dis 161 (1990) 977-981
87. Amicosante M., Richeldi L., Trenti G., Paone G., Campa M., Bisetti A., et al. Inactivation of polymerase inhibitors for M.tuberculosis DNA amplification in sputum by using capture resin. J Clin Microbiol 33 (1995) 629-630
88. Noordhoeck G.T., van Embden J.D.A., and Kolk A.H.J. Reliability of nucleic acid amplification for detection of Mycobacterium tuberculosis: an international collaborative quality control study among 30 laboratories. J Clin Microbiol 34 (1996) 2522-2525
89. Pfyffer G.E., Funke-Kissling P., Rundler E., and Weber R. Performance characteristics of the BDProbeTec system for direct detection of Mycobacterium tuberculosis complex in respiratory specimens. J Clin Microbiol 37 (1999) 137-140
90. Portaels F., Serruys E., De Beenhouwer H., et al. Evaluation of the Gen-Probe amplified Mycobacterium tuberculosis direct test for the routine diagnosis of pulmonary tuberculosis. Acta Clin Belg 51 (1996) 144-149
91. Shah S.J., Liu J., Buxton D., et al. Q-beta replicase-amplified assay for detection of Mycobacterium tuberculosis directly from clinical specimens. J Clin Microbiol 33 (1995) 1435-1441
92. Jonas V., Alden M.J., Curry J.I., Kamisango K., Knott C.A., Lankford R., et al. Detection and identification of Mycobacterium tuberculosis directly from sputum sediments by amplification of rRNA. J Clin Microbiol 31 (1993) 2410-2416
93. Devallois A., Legrand E., and Rastogi N. Evaluation of Amplicor MTB test as adjunct to smears and culture for direct detection of Mycobacterium tuberculosis in the French Caribbean. J Clin Microbiol 34 (1996) 1065-1068
94. Tortoli E., Lavinia F., and Simonetti M.T. Evaluation of a commercial ligase chain reaction kit (Abbott LCx) for direct detection of Mycobacterium tuberculosis in pulmonary and extrapulmonary specimens. J Clin Microbiol 35 (1997) 2424-2426
95. Catanzaro A., Perry S., Clarridge J.E., Dunbar S., Goodnight-White S., LoBue P.A., et al. The role of clinical suspicion in evaluating a new diagnostic test for active tuberculosis: results of a multicenter prospective trial. JAMA 283 (2000) 639-645
96. Lim T.K., Mukhopadhyay A., Gough A., Khoo K.L., Khoo S.M., Lee H., et al. Role of clinical judgment in the application of a nucleic acid amplification test for the rapid diagnosis of pulmonary tuberculosis. Chest 124 (2003) 902-908
97. Update: nucleic acid amplification tests for tuberculosis. MMWR 2000; 49: 593-4.
98. von Pirquet C. Frequency of tuberculosis in childhood. JAMA 52 (1907) 675-678
99. Palmer C.E., and Edwards L.B. Tuberculin test in retrospect and prospect. Arch Environ Health 15 (1967) 792-808
100. Menzies D. Interpretation of repeated tuberculin. Boosting, conversion, and reversion tests. Am J Respir Crit Care Med 159 (1999) 15-21
101. Fine P.E., Bruce J., Ponnighaus J.M., et al. Tuberculin sensitivity: conversions and reversions in a rural African population. Int J Tuberc Lung Dis 3 (1999) 962-975
102. Wang L., Turner M.O., Elwood R.K., et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurement. Thorax 57 (2002) 804-809
103. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 55 (2000) 887-901
104. Andersen P., Munk M.E., and Pollock J.M. Specific immune-based diagnosis of tuberculosis. Lancet 356 (2000) 1099-1104
105. Cockle P.J., Gordon S.V., Lalvani A., Buddle B.M., Hewinson R.G., and Vordermeier H.M. Identification of novel Mycobacterium tuberculosis antigens with potential as diagnostic reagents or subunit vaccine candidates by comparative genomics. Infect Immun 70 (2002) 6996-7003
106. Goletti D., Carrara S., Vincenti D., Saltini C., Rizzi E.B., Schinina V., et al. Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clin Microbiol Infect 12 (2006) 544-550
107. Lalvani A., Pathan A.A., McShane E., et al. Rapid detection of M. tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 163 (2001) 824-828
108. Pathan A.A., Wilkinson K., Klenerman P., et al. Direct ex vivo analysis of antigen-specific IFNγ-secreting CD4 T cells in M. tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 167 (2001) 5217-5225
109. Chapman A.L., Munkanta M., Wilkinson K.A., et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 16 (2002) 2285-2293
110. Ravn P., Munk M.E., Andersen A.B., et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 12 (2005) 491-496
111. Rothel J.S., and Andersen P. Diagnosis of latent Mycobacterium tuberculosis infection: is the demise of the Mantoux test imminent?. Expert Rev Anti Infect Ther 3 (2005) 981-993
112. Ewer K., Deeks J., Alvarez L., et al. Comparison of T-cell based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 361 (2003) 1168-1173
113. Kang Y.A., Lee W.H., Yoon H.I., et al. Discrepancy between the tuberculin skin test and the whole-blood interferon-γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. J Am Med Assoc 293 (2005) 2756-2761
114. Pai M., Gokhale K., Joshi R., et al. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole-blood interferon gamma assay with tuberculin skin testing. JAMA 293 (2005) 2746-2755
115. Brock I., Weldingh K., lillebaek T., et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 170 (2004) 65-69
116. Richeldi L., Ewer K., Losi M., et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 170 (2004) 288-295
117. Dheda K., Lalvani A., Miller R.F., et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS 19 (2005) 2038-2041
118. Mazurek G.H., Jereb J., Lobue P., Iademarco M.F., Metchock B., and Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 54 (2005) 49-55
119. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006 (www.rcplondon.ac.uk)
120. Rovatti E., Corradi M.P., Amicosante M., Tartoni P.L., Panini W., Ancora A., et al. Evaluation of a western blot serum test for the diagnosis of Mycobacterium tuberculosis infection. Eur Respir J 1 (1996) 9288-9292
121. Franchi A., Amicosante M., Rovatti E., Bonini R., Marchegiano P., Girardi E., et al. Evaluation of a western blot test as a potential screening tool for occupational exposure to Mycobacterium tuberculosis in health care workers. J Occup Environ Med 42 (2000) 64-68
122. Davidow A., Kanaujia G.V., Shi L., Kaviar J., Guo X., Sung N., et al. Antibody profiles characteristic of Mycobacterium tuberculosis infection state. Infect Immun 73 (2005) 6846-6851
123. Middlebrook G., and Dubos R.J. Specific serum agglutination of erythrocytes sensitized with extracts of tubercle bacilli. J Exp Med 88 (1948) 521
124. Ma Y., Wang Y.M., and Daniel T.M. Enzyme-linked immunosorbent assay using Mycobacterium tuberculosis antigen 5 for the diagnosis of pulmonary tuberculosis in China. Am Rev Respir Dis 134 (1986) 1273-1275
125. Charpin D., Herbault H., Gevaudan M.J., et al. Value of ELISA using A60 antigen in the diagnosis of active pulmonary tuberculosis. Am Rev Respir Dis 142 (1990) 380-384
126. Cocito C.G. Properties of the mycobacterial antigen complex A60 and its applications to the diagnosis and prognosis of tuberculosis. Chest 100 (1991) 1687-1693
127. Alifano M., De Pascalis R., Sofia M., Faraone S., and Del Pezzo M. Covelli IEvaluation of IgA-mediated humoral immune response against the mycobacterial antigen P-90 in diagnosis of pulmonary tuberculosis. Chest 111 (1997) 601-605
128. Sada E., Aguilar D., Torres M., and Herrera T. Detection of lipoarabinomannan as a diagnostic test for tuberculosis. J Clin Microbiol 30 (1992) 2415-2418
129. Ratanasuwan W., Kreiss J.K., Nolan C.M., et al. Evaluation of the MycoDot test for the diagnosis of tuberculosis in HIV seropositive and seronegative patients. Int J Tuberc Lung Dis 1 (1997) 259-264
130. Wilkins E.G.L., and Ivanyi J. Potential value of serology for diagnosis of extrapulmonary tuberculosis. Lancet 336 (1990) 641-644
131. Kanaujia G.V., Lam P.K., Perry S., Brusasca P.N., Catanzaro A., and Gennaro M.L. Integration of microscopy and serodiagnostic tests to screen for active tuberculosis. Int J Tuberc Lung Dis 9 (2005) 1120-1126
132. Chan E.D., Heifets L., and Iseman M.D. Immunologic diagnosis of tuberculosis: a review. Tuberc Lung Dis 80 (2000) 131-140
133. Grigg E.R. The arcana of tuberculosis with a brief epidemiologic history of the disease in the USA. Am Rev Tuberc 78 (1958) 151-172
134. Forlanini C. Primo caso di tisi pulmonare monolaterale avanzata curato felicemente col pneumotorace artificiale. Gazz Med Torino 46 (1895) 857-858
135. Schatz A., and Waksman S.A. Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 57 (1944) 244-248